These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1016 related items for PubMed ID: 10840432

  • 1. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H.
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [Abstract] [Full Text] [Related]

  • 2. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 3. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [Abstract] [Full Text] [Related]

  • 4. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H, Lau W, Bergstralh E, Blute ML.
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [Abstract] [Full Text] [Related]

  • 5. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer.
    Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT.
    Urology; 1997 Jul; 50(1):93-9. PubMed ID: 9218025
    [Abstract] [Full Text] [Related]

  • 6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [Abstract] [Full Text] [Related]

  • 7. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [Abstract] [Full Text] [Related]

  • 8. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
    Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ.
    J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
    [Abstract] [Full Text] [Related]

  • 9. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [Abstract] [Full Text] [Related]

  • 10. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications.
    Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC.
    J Urol; 2001 Mar; 165(3):864-6. PubMed ID: 11176487
    [Abstract] [Full Text] [Related]

  • 11. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW.
    Cancer; 2004 Dec 01; 101(11):2549-56. PubMed ID: 15470681
    [Abstract] [Full Text] [Related]

  • 12. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V.
    BJU Int; 2006 May 01; 97(5):985-91. PubMed ID: 16643480
    [Abstract] [Full Text] [Related]

  • 13. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA.
    J Urol; 2007 Aug 01; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [Abstract] [Full Text] [Related]

  • 14. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H.
    J Urol; 2003 Nov 01; 170(5):1872-6. PubMed ID: 14532796
    [Abstract] [Full Text] [Related]

  • 15. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, SEARCH Database Study Group.
    J Urol; 2003 Jun 01; 169(6):2129-35. PubMed ID: 12771734
    [Abstract] [Full Text] [Related]

  • 16. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
    Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H.
    J Urol; 2001 Jan 01; 165(1):119-25. PubMed ID: 11125379
    [Abstract] [Full Text] [Related]

  • 17. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ, Partin AW, Epstein JI, Walsh PC.
    Cancer; 2004 Apr 15; 100(8):1646-9. PubMed ID: 15073852
    [Abstract] [Full Text] [Related]

  • 18. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT.
    J Urol; 2005 Sep 15; 174(3):903-7. PubMed ID: 16093984
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS, Bianco FJ, Scardino PT, Eastham JA.
    J Urol; 2006 Aug 15; 176(2):564-8. PubMed ID: 16813890
    [Abstract] [Full Text] [Related]

  • 20. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.
    Cancer; 2007 Apr 01; 109(7):1273-8. PubMed ID: 17315165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.